Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | DDO | Q99489 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624496 | 0.89 | NPC1 (0.50) | ARNPC1RAB9AAOC3DAO | |
| SCHEMBL10613155 | 0.87 | AOC3 (0.52) | ARNPC1RAB9AAOC3DAO | |
| SCHEMBL8960942 | 0.85 | FLT3 (0.44) | ARNPC1RAB9AAOC3DAO | |
| SCHEMBL28782688 | 0.85 | BRD4 (0.47) | ARNPC1RAB9AAOC3KDM4E | |
| SCHEMBL31465196 | 0.81 | TUBB4A (0.37) | ARNPC1RAB9AAOC3DAO | |
| SCHEMBL6824048 | 0.80 | MEN1 (0.54) | NPC1RAB9ADAOKDM4EMAPT | |
| SCHEMBL28855235 | 0.79 | NPC1 (0.47) | ARNPC1RAB9AKDM4EMAPT | |
| SCHEMBL9328485 | 0.79 | AOC3 (0.52) | ARNPC1RAB9AAOC3DAO | |
| SCHEMBL30990546 | 0.79 | AOC3 (0.52) | ARNPC1RAB9AAOC3DAO | |
| SCHEMBL18427579 | 0.77 | AOC3 (0.50) | ARNPC1RAB9AAOC3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816884-B | Synthetic method of arylthio naphthol, naphthylamine compound and thiophenyl indole compound | 南开大学 | 2022-05-17 | — | — | CN | claimed |
| CN-113816884-A | Synthetic method of arylthio naphthol, naphthylamine compound and thiophenyl indole compound | 南开大学 | 2021-12-21 | — | — | CN | claimed |
| US-20250076301-A1 | BIOMARKER FOR PROSTATE CANCER | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-03-06 | — | — | US | disclosed |
| CN-114814013-B | Method for rapidly screening unknown chemical hazard residues in aquatic products based on high-resolution mass spectrum database | 中国海洋大学 | 2023-06-02 | — | — | CN | disclosed |
| CN-113816884-B | Synthetic method of arylthio naphthol, naphthylamine compound and thiophenyl indole compound | 南开大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-113816884-A | Synthetic method of arylthio naphthol, naphthylamine compound and thiophenyl indole compound | 南开大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| US-4157399-A | Benzo(B)thiophenes | PARCOR (FR) | 1979-06-05 | — | — | US | disclosed |
| US-3933841-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | AR 4473/4885NPC1 789/4885RAB9A 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.